Mallinckrodt Pharmaceuticals Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 2/28/2020)
| Balance Sheet | Total Assets | 10,338,900,000.00 | ROE | – |
| Balance Sheet | Total Equity | 1,940,700,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -133,000,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 609,900,000.00 | – | – |
| Cashflow | Operating Cash Flow | 742,900,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -11.88 | Div. Yield | – |
| Income | Net Income | -996,500,000.00 | P/E | – |
| Income | Shares Outstanding | 83,880,500.00 | P/B | – |
| Income | Total Revenue | 3,162,500,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company's segments include Specialty Brands, Specialty Generics and Nuclear Imaging. Its Specialty Brands segment produces and markets branded pharmaceutical and biopharmaceutical products for autoimmune and rare diseases; immunotherapy and neonatal respiratory critical care therapies, and central nervous system drugs. Its Specialty Generics segment produces specialty generic pharmaceuticals and active pharmaceutical ingredients (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its Nuclear Imaging segment manufactures and markets radiopharmaceuticals (nuclear medicine).
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.mallinckrodt.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more